A new systematic review published in JAMA Network Open indicates that the timing of immunotherapy administration may significantly affect survival outcomes in patients with advanced solid tumors. The analysis, which pooled data from 29 studies encompassing more than 6,000 patients, found that earlier use of immune checkpoint inhibitor therapies was associated with improved survival endpoints.
The review focused on patients with late-stage cancers and compared outcomes based on when in the treatment course immunotherapy was initiated. Results showed that earlier timing was linked to gains in both overall survival and progression-free survival. However, the authors caution that prospective validation is required before any changes to scheduling can be broadly adopted in clinical practice.
Immune checkpoint inhibitors have revolutionized cancer treatment in recent years, but optimal sequencing with other therapies remains an area of active investigation. This study adds to the growing body of evidence that when these drugs are given may be as important as which drugs are used.
The findings could have implications for companies developing immunotherapy treatments. For example, Calidi Biotherapeutics Inc. (NYSE American: CLDI) is among the for-profit entities engaged in advancing immunotherapies, and more rigorous studies on timing could influence their clinical development strategies.
While the review provides compelling data, experts emphasize that these results are preliminary and not yet practice-changing. Patients should continue to follow their oncologist's recommendations regarding treatment schedules. The study underscores the need for further research to refine the use of these powerful drugs.
